ACA
TARA icon

Acorn Capital Advisors’s Protara Therapeutics TARA Stock Holding History

Acorn Capital Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.13M Hold
1,752,115
– – 2.59% 10
2025
Q4 		$9.34M Hold
1,752,115
– – 3.16% 10
2025
Q3 		$7.62M Hold
1,752,115
– – 3.87% 9
2025
Q2 		$5.31M Buy
1,752,115
+472,315
+37% +$1.63M 3.47% 11
2025
Q1 		$5.45M Hold
1,279,800
– – 3.64% 8
2024
Q4 		$6.76M Buy
+1,279,800
New +$4.13M 3.64% 10

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acorn Capital Advisors's TARA Position: Q1 2026 in Review

Acorn Capital Advisors held its Protara Therapeutics (TARA) position steady in Q1 2026 at 1,752,115 shares worth $9.13M. The position accounts for 2.59% of the portfolio, ranked #10.

Acorn Capital Advisors first reported a position in TARA in Q4 2024 and has held it in 6 quarters since. The position peaked at $9.34M in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Acorn Capital Advisors held 1,752,115 shares of Protara Therapeutics worth $9.13M as of Q1 2026.
  • Acorn Capital Advisors left its Protara Therapeutics share count unchanged in Q1 2026.
  • Protara Therapeutics made up 2.59% of Acorn Capital Advisors's portfolio in Q1 2026, its #10 holding.
  • Acorn Capital Advisors first reported a position in Protara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Acorn Capital Advisors's Protara Therapeutics position peaked at $9.34M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.